Update From the San Antonio Breast Cancer Symposium

December 19, 2013
12:00pm to 01:00pm
2013-12-19 12:00:00 2013-12-19 13:00:00 America/New_York Update From the San Antonio Breast Cancer Symposium  

Hear the latest research that your doctors and leading breast cancer experts are talking about, including updates on early stage and metastatic breast cancer. Learn what's new in neoadjuvant treatment, targeted and hormonal therapies and methods to reduce risk of recurrence. Discover what’s in the pipeline for triple-negative and HER2-positive cancer and much more.

During our free December webinar, William J. Gradishar MD, FACP helped you
  • understand the latest research on early-stage and metastatic breast cancer.
  • learn about updates in neoadjuvant treatments, hormonal therapies and new methods to reduce the risk of recurrence.
  • discover new research on triple-negative and HER 2-positive cancers and much more.

About Our Speaker

William J. Gradishar, MD, FACP is Betsy Bramsen professor of breast oncology in the division of hematology and medical oncology, department of medicine, at the Feinberg School of Medicine at Northwestern University in Chicago, Ill., and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He serves as director of the Maggie Daley Center for Women’s Cancer Care and has been chair of the Annual Lynn Sage Breast Cancer Symposium since its inception. His research focuses on the development of novel therapeutics for the treatment of breast cancer.

A fellow of the American College of Physicians, Dr. Gradishar is also a member of the American Association for Cancer Research, the American Federation for Clinical Research, and the Association of Subspecialty Professors.  He is chair-elect of the ASCO Professional Development Committee as well as a member of ASCO’s Scientific Program Committee and the Breast Cancer Core Committee. He serves as co-chair of the Developmental Therapeutics Working Group of the Eastern Cooperative Oncology Group, the Committee on Cancer of the American College ofSurgeons, the National Comprehensive Cancer Network (NCCN) Breast CancerGuidelines Panel, and the NCCN Breast Cancer Prevention Panel. In addition, he is a consultant to the Oncology Drug Advisory Committee of the FDA.  An editorial board member of numerous oncology journals, Dr. Gradishar publishes in the area of breast cancer therapeutics,with a focus on new endocrine therapy, chemotherapy and biologic agents. He was recently awarded the Betsy Bramsen Endowed Chair of Breast Oncology at Northwestern University.